Top

Reactions Weekly

Published in:

01-05-2017 | Case report

Simeprevir/sofosbuvir/ribavirin

Anaemia: 2 case reports

Published in: Reactions Weekly | Issue 1/2017

Excerpt

Author Information

An event is serious (FDA MedWatch definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* requires intervention to prevent permanent impairment or damage

…

Bruno G, et al. Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir+/-ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study. International Journal of Antimicrobial Agents 49: 296-301, No. 3, Mar 2017. Available from: URL: http://doi.org/10.1016/j.ijantimicag.2016.11.030 - ItalyCrossRefPubMed

Title: Simeprevir/sofosbuvir/ribavirin
Anaemia: 2 case reports
Publication date: 01-05-2017
Publisher: Springer International Publishing
Published in: Reactions Weekly / Issue 1/2017
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-017-30103-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Simeprevir/sofosbuvir/ribavirin

Anaemia: 2 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2017

Aspirin/rivaroxaban

Valaciclovir overdose

Hydromorphone/pregabalin

Staphylococcin

Propofol

Heparin